Welcome to our dedicated page for Beyondspring news (Ticker: BYSI), a resource for investors and traders seeking the latest updates and insights on Beyondspring stock.
BeyondSpring Inc. (NASDAQ: BYSI) generates a steady flow of news centered on the clinical and regulatory progress of its lead asset, Plinabulin, and on its corporate and financing activities. As a clinical-stage biopharmaceutical company focused on cancer, BeyondSpring’s updates often highlight new data from phase 2 and phase 3 trials in non-small cell lung cancer (NSCLC) and other tumor types, as well as mechanistic findings related to Plinabulin’s dendritic cell maturation and immune-modulating properties.
News releases frequently cover results from major oncology conferences and journals. Examples include presentations at the American Society of Clinical Oncology (ASCO), the IASLC/ASCO North America Conference on Lung Cancer (NACLC), the Society for Immunotherapy of Cancer (SITC), Immuno-Oncology 360°, and ESMO Asia, along with peer-reviewed publications in outlets such as Lancet Respiratory Medicine and Med (Cell Press). These communications describe outcomes from the DUBLIN‑3 phase 3 trial, the 303 and 302 phase 2 studies, and basket trials combining Plinabulin with checkpoint inhibitors, chemotherapy, and radiation.
Investors following BYSI news can also expect regular financial updates, including quarterly results, cash position, and operating expense trends, as well as 10‑K filing announcements. Corporate news items address equity financings, such as registered offerings of ordinary shares, and strategic transactions involving BeyondSpring’s equity stake in SEED Therapeutics, a targeted protein degradation company co-founded by BeyondSpring.
For market participants tracking oncology pipelines, the BYSI news stream provides insight into Plinabulin’s clinical performance, safety profile, biomarker research, and planned registrational strategies, including the company’s intention to advance confirmatory trials like DUBLIN‑4. Bookmarking the news page allows readers to monitor how new data, conference presentations, and SEC-referenced announcements may influence the development trajectory of Plinabulin and BeyondSpring’s broader strategy.
BeyondSpring, a biopharmaceutical company focusing on innovative cancer therapies, announced the pricing of a public offering of 1,930,000 ordinary shares at $13.00 each, alongside a private placement of 384,615 shares to Decheng Capital. The total gross proceeds are projected to be approximately $30.1 million. Funds will support the commercialization of Plinabulin and further clinical development. The public offering is set to close on June 23, 2020, while the private placement is expected on July 2, 2020.
BeyondSpring Inc. (BYSI) announced a public offering of ordinary shares, expected to raise funds for the commercialization of its lead therapy, Plinabulin, and to support ongoing clinical development. The offering also includes a private placement with Decheng Capital. Jefferies and William Blair are acting as joint book-running managers. The offering is subject to market conditions and may not proceed as planned. BeyondSpring is focused on developing innovative immuno-oncology therapies, with Plinabulin currently in multiple Phase 3 clinical trials.
BeyondSpring (NASDAQ: BYSI) announced positive topline results from the PROTECTIVE-2 Phase 3 trial, evaluating Plinabulin in combination with Neulasta against Neulasta alone. The primary endpoint of reducing Grade 4 neutropenia was met (p0.01), along with key secondary endpoints for the duration of severe neutropenia (p<0.05). The trial showed that the combination offers early protection during the first chemotherapy cycle, potentially addressing a significant unmet medical need in cancer care. A conference call will provide further insights.
BeyondSpring (NASDAQ: BYSI) announced promising results from the PROTECTIVE-2 Phase 2 trial, showcasing its lead asset Plinabulin in combination with Neulasta. The study revealed a 72% reduction in chemotherapy dose adjustments, with only 6.3% of patients needing dose reduction compared to 22.7% in the Neulasta-only group. Additionally, no patients downgraded their chemotherapy regimen in the Plinabulin group, potentially leading to better long-term survival outcomes. The improvements address the critical issue of Grade 4 neutropenia prevalent during high-risk chemotherapy.
BeyondSpring (NASDAQ: BYSI) announced that its Phase 3 Dublin-3 clinical trial for Plinabulin in non-small cell lung cancer (NSCLC) has received a favorable recommendation from the Data & Safety Monitoring Board (DSMB) after reviewing data from over 500 patients. The trial aims to evaluate the efficacy of Plinabulin combined with docetaxel compared to docetaxel alone in second- and third-line EGFR wild-type NSCLC patients. Previous Phase 2 results showed that this combination significantly extends overall survival while reducing severe neutropenia rates.
Summary not available.
Summary not available.
Summary not available.